Organogenesis

Q2 FY2026 EarningsQ2 FY26 missed consensus significantly as regulatory headwinds and reimbursement policy shifts triggered a material revenue decline. Revenue of $43.8M fell -19.35% short of expectations ($54.3M), primarily due to a 61% YoY plunge in Advanced Wound Care sales following LCD coverage withdrawals. The Company recorded a massive Net Loss of -$96.3M vs. -$45.9M expected, driven by a $45.4M tax charge to establish a full valuation allowance against deferred tax assets. Management has initiated major restructuring, reducing headcount by 18% in Q2, while delaying the Dermagraft relaunch due to weak market conditions.